Importantly, we show that PAD is an effective therapeutic regimen that can be extended to the most prevalent HR‐defective genotypes in PDAC including ATM, BRCA1, BRCA2 and PALB2 in a preclinical setting. Here, PALB2 is linked to peripheral arterial disease.